IP Library Granted Patent US 10,562,870
Granted Patent B2
US 10,562,870 · App. 15/668,984 · Granted Feb 18, 2020

Prodrugs of riluzole and their method of use

Inventors: Garry Robert Smith (Royersford, PA); Allen B. Reitz (Lansdale, PA); Mark Mcdonnell (Lansdale, PA); Suzie Chen (Highland Park, NJ); Matthew D. Vera (Collegeville, PA); Benjamin E. Blass (Eagleville, PA); Jeffery Claude Pelletier (Lafayette Hill, PA); Venkata N. Velvadapu (Philadelphia, PA); Jay Edward Wrobel (Lawrenceville, NJ)
Assignee: Biohaven Pharmaceutical Holding Company Ltd.
C07D277/82A61K31/428A61K45/06C07D417/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,562,870
App. No.
15/668,984
Granted
Feb 18, 2020
Kind
B2
Abstract

Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.

Claims (23)

1. A compound having formula (I):

including hydrates, solvates, pharmaceutically acceptable salts, and complexes thereof, wherein:

R 1 is OR 2 ;

R 2 is selected from the group consisting of C3-C6 alkyl and CH 2 (CH 2 ) n NR 8a R 8b ;

R 8a is optionally substituted C1-C6 alkyl;

R 8b is optionally substituted C2-C6 alkyl;

n is 1 or 2.

2. A compound having formula (I):

including hydrates, solvates, pharmaceutically acceptable salts, and complexes thereof, wherein:

R 1 is CH 2 CH 2 CO 2 R 4 ,

R 4 is selected from the group consisting of hydrogen and optionally substituted C1-C6 Alkyl.

3. A compound having formula (I):

including hydrates, solvates, pharmaceutically acceptable salts, and complexes thereof, wherein:

R 1 is CH 2 CH 2 CONHR 5 ;

R 5 is selected from the group consisting of hydrogen, optionally substituted C1-C6 Alkyl, CH 2 CH 2 NR 10a R 10b , and CH 2 R 11 ;

R 10a and R 10b are each independently is selected from the group consisting of hydrogen and optionally substituted C1-C6 alkyl;

or

R 10a and R 10b and are taken together with the atom to which they are bound to form an optionally substituted ring having 5 to 6 ring atoms;

or

R 10a and R 10b and are taken together with the atom to which they are bound to form an optionally substituted ring having 5 to 6 ring atoms containing an oxygen;

or

R 10a and R 10b and are taken together with the atom to which they are bound to form an optionally substituted ring having 5 to 6 ring atoms containing two nitrogen atoms;

R 11 is selected from the group consisting of optionally substituted phenyl and optionally substituted heteroaryl.

Assignments (5)
SECURITY INTEREST Recorded May 1, 2025
From: BIOHAVEN THERAPEUTICS LTD
To: BEETLEJUICE SA LLC, AS PURCHASER AGENT
Reel/Frame 071147/0260 →
RELEASE OF SECURITY INTEREST Recorded Apr 27, 2025
From: SIXTH STREET SPECIALTY LENDING, INC.
To: BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.; BIOHAVEN THERAPEUTICS LTD.; BIOHAVEN PHARMACEUTICAL IRELAND DESIGNATED ACTIVITY COMPANY
Reel/Frame 071083/0399 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 15, 2023
From: CHEN, SUZIE
To: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
Reel/Frame 063639/0272 →
PATENT SECURITY AGREEMENT Recorded Aug 7, 2020
From: BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.; BIOHAVEN THERAPEUTICS LTD; BIOHAVEN PHARMACEUTICAL IRELAND DESIGNATED ACTIVITY COMPANY
To: SIXTH STREET SPECIALTY LENDING, INC., AS ADMINISTRATIVE AGENT
Reel/Frame 053428/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 5, 2020
From: BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.
To: BIOHAVEN THERAPEUTICS LTD.
Reel/Frame 053404/0315 →
Continuity (3)
Continuation 14385551
Provisional Application 61612210 · Mar 16, 2012
Related Publication 20170334870A1 · Nov 23, 2017